Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Urology
Published in: BMC Urology 1/2018

Open Access 01-12-2018 | Research article

Expression and clinical significance of Caveolin-1 in prostate Cancer after transurethral surgery

Authors: Xiaoming Wang, Zhigui Liu, Zhanbin Yang

Published in: BMC Urology | Issue 1/2018

Login to get access

Abstract

Background

Prostate cancer is a common malignancy of the male genitourinary system that occurs worldwide. The current research aims to investigate caveolin-1 expression in prostate cancer tissue and its relationship with pathological grade, clinical pathologic staging, and preoperative prostate-specific antigen (PSA) levels.

Methods

From January 2012 to December 2014, samples from 47 patients with prostate cancer who had received transurethral prostatic resection (TURP) and 20 patients with benign prostatic hyperplasia were collected at the First Affiliated Hospital of Guangxi Medical University. Caveolin-1 was detected by streptavidin-perosidase (SP) immunohistochemical staining in pathological tissue slices. The results were statistically analyzed for pathological grade, clinical stage, and preoperative PSA level.

Results

The expression of caveolin-1 was significantly higher in prostate cancer samples than in benign prostatic hyperplasia samples (P < 0.05), and caveolin-1 expression was significantly different among the pathological grades of poorly, moderately and well-differentiated prostate cancer (P < 0.05). The difference in caveolin-1 expression was significant for different clinical stages (T1-T2 and T3-T4) of prostate cancer (P < 0.05). The difference in caveolin-1 expression was not significant among samples with different preoperative PSA levels (0–10, 10–100 and > 100 μg/L) (P > 0.05).

Conclusions

Caveolin-1 is closely related to the pathological grade and clinical stage of prostate cancer after transurethral surgery, and it may be a novel tumor marker for prostate cancer. The expression of caveolin-1 is not associated with preoperative serum PSA levels.
Literature
1.
Wong ECL, Kapoor A. Epidemiology of prostate and kidney cancer in the aboriginal population of Canada: a systematic review. Can Urol Assoc J. 2017;11:E222–E32.CrossRef
2.
Trama A, Botta L, Nicolai N, Rossi PG, Contiero P, Fusco M, et al. Prostate cancer changes in clinical presentation and treatments in two decades: an Italian population-based study. Eur J Cancer. 2016;67:91–8.CrossRef
3.
Rainato G, Fabricio AS, Zancan M, Peloso L, Dittadi R, Barichello M, et al. Evaluating serum insulin-like growth factor 1 and insulin-like growth factor binding protein 3 as markers in prostate cancer diagnosis. Int J Biol Markers. 2016;31:e317–e23.CrossRef
4.
Stephan C, Jung K, Miller K, Ralla B. New biomarkers in serum and urine for detection of prostate cancer. Aktuelle Urol. 2015;46:129–43.CrossRef
5.
Dickinson J, Shane A, Tonelli M, Connor GS, Joffres M, Singh H, et al. Trends in prostate cancer incidence and mortality in Canada during the era of prostate-specific antigen screening. Cmaj Open. 2016;4:E73–E9.CrossRef
6.
Terada N, Akamatsu S, Kobayashi T, Inoue T, Ogawa O, Antonarakis ES. Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications. Ther Adv Med Oncol. 2017;9:565–73.CrossRef
7.
Sugie S, Mukai S, Yamasaki K, Kamibeppu T, Tsukino H, Kamoto T. Significant Association of Caveolin-1 and Caveolin-2 with prostate Cancer progression. Cancer Genomics Proteomics. 2015;12:391–6.PubMed
8.
Yang HJ, Feng P, Wang L, Li ZC, Ma SP, Wang M, et al. Caveolin-1 mediates gene transfer and cytotoxicity of polyethyleneimine in mammalian cell lines. Mol Cell Biochem. 2015;402:203–11.CrossRef
9.
Anwar SL, Wahyono A, Aryandono T, Haryono SJ. Caveolin-1 in breast Cancer: single molecule regulation of multiple key signaling pathways. Asian Pac J Cancer Prev. 2015;16:6803–12.CrossRef
10.
Simpkins SA, Hanby AM, Holliday DL, Speirs V. Clinical and functional significance of loss of caveolin-1 expression in breast cancer-associated fibroblasts. J Pathol. 2012;227:490–8.CrossRef
11.
Garnett DJ. Caveolae as a target to quench autoinduction of the metastatic phenotype in lung cancer. J Cancer Res Clin Oncol. 2016;142:611–8.CrossRef
12.
Reis ST, Viana NI, Leite KR, Diogenes E, Antunes AA, Iscaife A, et al. Role of genetic polymorphisms in the development and prognosis of sporadic and familial prostate Cancer. PLoS One. 2016;11:e0166380.CrossRef
13.
Bocci G, Fioravanti A, Orlandi P, Di DT, Natale G, Fanelli G, et al. Metronomic ceramide analogs inhibit angiogenesis in pancreatic Cancer through up-regulation of Caveolin-1 and Thrombospondin-1 and Down-regulation of cyclin D1. Neoplasia. 2012;14:833–45.CrossRef
14.
Shen X-J, Zhang H, Tang G-S, Wang X-D, Zheng R, Wang Y, et al. Caveolin-1 is a modulator of fibroblast activation and a potential biomarker for gastric Cancer. Int J Biol Sci. 2015;11:370–9.CrossRef
15.
Ma W, Wang DD, Li L, Feng YK, Gu HM, Zhu GM, et al. Caveolin-1 plays a key role in the oleanolic acid-induced apoptosis of HL-60 cells. Oncol Rep. 2014;32:293–301.CrossRef
16.
Friedrich T, Richter B, Gaiser T, Weiss C, Janssen KP, Einwächter H, et al. Deficiency of caveolin-1 in Apc(min/+) mice promotes colorectal tumorigenesis. Carcinogenesis. 2013;34:2109–18.CrossRef
17.
Xu J, Agyemang S, Qin Y, Aysola K, Giles M, Oprea G, et al. A novel pathway that links Caveolin-1 Down-regulation to BRCA1 dysfunction in serous epithelial ovarian Cancer cells. Enliven Challenges in cancer detection and therapy. 2014;1:004.CrossRef
18.
Tse EY, Ko FC, Tung EK, Chan LK, Lee TK, Ngan ES, et al. Caveolin-1 overexpression is associated with hepatocellular carcinoma tumourigenesis and metastasis. J Pathol. 2012;226:645–53.CrossRef
19.
Huang C, Qiu Z, Wang L, Peng Z, Jia Z, Logsdon CD, et al. A novel FoxM1-caveolin signaling pathway promotes pancreatic cancer invasion and metastasis. Cancer Res. 2012;72:655–65.CrossRef
20.
Pancotti F, Roncuzzi L, Maggiolini M, Gaspericampani A. Caveolin-1 silencing arrests the proliferation of metastatic lung cancer cells through the inhibition of STAT3 signaling. Cell Signal. 2012;24:1390–7.CrossRef
21.
Masuelli L, Budillon A, Marzocchella L, Mrozek MA, Vitolo D, Di Gennaro E, et al. Caveolin-1 overexpression is associated with simultaneous abnormal expression of the E-cadherin/α-β catenins complex and multiple ErbB receptors and with lymph nodes metastasis in head and neck squamous cell carcinomas. J Cell Physiol. 2012;227:3344–53.CrossRef
22.
Steffens S, Schrader AJ, Blasig H, Vetter G, Eggers H, Tränkenschuh W, et al. Caveolin 1 protein expression in renal cell carcinoma predicts survival. BMC Urol. 2011;11:25.CrossRef
23.
Steiner I, Jung K, Miller K, Stephan C, Erbersdobler A. Expression of endothelial factors in prostate cancer: a possible role of caveolin-1 for tumour progression. Oncol Rep. 2012;27:389–95.PubMed
24.
Mohammed DA, Helal DS. Prognostic significance of epithelial/stromal caveolin-1 expression in prostatic hyperplasia, high grade prostatic intraepithelial hyperplasia and prostatic carcinoma and its correlation with microvessel density. J Egypt Natl Canc Inst. 2017;29:25–31.CrossRef
25.
Bennett NC, Hooper JD, Johnson DW, Gobe GC. Expression profiles and functional associations of endogenous androgen receptor and caveolin-1 in prostate cancer cell lines. Prostate. 2014;74:478–87.CrossRef
26.
Nassar ZD, Moon H, Duong T, Neo L, Hill MM, Francois M, et al. PTRF/Cavin-1 decreases prostate cancer angiogenesis and lymphangiogenesis. Oncotarget. 2013;4:1844–55.CrossRef
27.
Lee H, Park DS, Razani B, Russell RG, Pestell RG, Lisanti MP. Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (−/−) null mice show mammary epithelial cell hyperplasia. Am J Pathol. 2002;161:1357–69.CrossRef
28.
Lee H, Volonte’ D, Galbiati F, Iyengar P, Lublin DM, Bregman DB, et al. Constitutive and growth factor-regulated phosphorylation of caveolin-1 occurs at the same site (Tyr-14) in vivo: identification of a c-Src/Cav-1/Grb7 signaling cassette. Mol Endocrinol. 2000;14:1750–5.CrossRef
29.
Tahir SA, Yang G, Ebara S, Timme TL, Satoh T, Li L, et al. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res. 2001;61:3882–5.PubMed
30.
Li L, Ren C, Yang G, Goltsov AA, Tabata K, Thompson TC. Caveolin-1 promotes autoregulatory, Akt-mediated induction of cancer-promoting growth factors in prostate cancer cells. Mol Cancer Res. 2009;7:1781–91.CrossRef
31.
Wang S, Zhang C, Liu Y, Xu C, Chen Z. Functional polymorphisms of caveolin-1 variants as potential biomarkers of esophageal squamous cell carcinoma. Biomarkers. 2014;19:652–9.CrossRef
32.
Karam JA, Lotan Y, Roehrborn CG, Ashfaq R, Karakiewicz PI. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. Prostate. 2007;67:614–22.CrossRef
Metadata
Title
Expression and clinical significance of Caveolin-1 in prostate Cancer after transurethral surgery
Authors
Xiaoming Wang
Zhigui Liu
Zhanbin Yang
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2018
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/s12894-018-0418-4

Other articles of this Issue 1/2018

BMC Urology 1/2018 Go to the issue

Research article

What predicts emotional response in men awaiting prostate biopsy?

Research article

Knowledge and attitude for overactive bladder care among women: development and measurement

Research article

The evaluation of nocturia in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and the analysis of the curative effect after medical or placebo therapy for nocturia: a randomized placebo-controlled study

Technical advance

Minimally invasive surgical treatment on delayed uretero-vaginal fistula

Research article

Observation versus treatment among men with favorable risk prostate cancer in a community-based integrated health care system: a retrospective cohort study

Research article

Pre- and intra-operative predictors of postoperative hospital length of stay in patients undergoing radical prostatectomy for prostate cancer in China: a retrospective observational study